Market Signal Briefing

HDFC Bank Ltd., India's largest private sector lender, reported a stronger-than-expected profit for the September quarter, supported by steady loan growth and improving asset quality, even as pressure on margins persisted.

HomeMarketsCommodities CornerCommodities CornerCentral banks view gold as a ‘key, liquid component of their reserves’Published: Oct. 18, 2025 at 7:00 a.m. ET

Germany’s central bank, the Deutsche Bundesbank, holds the world’s second-largest gold reserves, behind the U.S. Photo: Deutsche Bundesbank/Agence France-Presse/Getty ImageGold prices at record highs sounds like a broken record, but central banks have continued to buy more than they’re selling, even with prices for the precious metal at their highest levels ever.

“Central banks continue to be consistent and strategic buyers of gold, even at record prices, because of the role it plays in strengthening their reserve portfolios,” Joe Cavatoni, senior market strategist at the World Gold Council, said in comments sent to MarketWatch Friday.

SummaryThis article provides a top-down analysis of the industrial sector, focusing on value and quality metrics.Transportation remains slightly undervalued, while aerospace/defense is the most overvalued subsector based on historical averages.FIDU and XLI are nearly equivalent for long-term investors, but XLI offers higher liquidity and better recent performance.Nine stocks that are cheaper than their peers in October.Quantitative Risk & Value members get exclusive access to our real-world portfolio. See all our investments here »Monty Rakusen/DigitalVision via Getty Images

This monthly article series reports subsector metrics, aiming at a top-down analysis of the industrials sector. It may also help analyze sector ETFs such as Industrial Select Sector SPDR ETF (XLI) and Fidelity MSCI

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in TSM over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

The world’s largest investment management firm, BlackRock (NYSE: BLK), has disclosed a 5.4% ownership stake in biopharmaceutical company Sellas Life Sciences Group (NASDAQ: SLS).

Specifically, the stake amounts to 5,686,886 shares, giving the investment giant voting control in the company, according to a Schedule 13G filing with the U.S. Securities Exchange Commission.

BlackRock SLS stock transaction. Source: SEC
Notably, BlackRock’s endorsement comes at a crucial time as SLS stock has shown strong bullish momentum in recent sessions. In after-hours trading on Friday, the stock rallied 38%, having closed the day’s session at $2.14, marking a 100% gain year to date.

SLS YTD stock price chart. Source: Google Finance
SLS stock fundamentals 
At the same time, the firm’s fundamentals appear to support potential sustained growth. Sellas Life Sciences, a late-stage biotechnology firm, has recently demonstrated meaningful clinical progress across its pipeline.

The company’s lead candidate, galinpepimut-S (GPS), is currently in a Phase 3 trial known as REGAL, targeting acute myeloid leukemia (AML). The independent data-monitoring committee overseeing the study confirmed that the trial could proceed without modification after a positive interim safety review. 

Median survival among patients has reportedly exceeded 13.5 months, more than double the historical average for standard treatments. The final data readout is expected by the end of 2025.

Sellas’s second key notable program, SLS009 (tambiciclib), a selective CDK9 inhibitor also targeting AML, has produced encouraging Phase 2 results. 

To this end, part of Friday’s rally came after reports that SLS009 showed strong preclinical results in T-cell prolymphocytic leukemia, improving survival and reducing tumor burden both alone and in combination with venetoclax.

The U.S. Food and Drug Administration (FDA) has already granted Sellas Fast Track and Orphan Drug designations for both programs, with guidance to initiate a first-line AML trial for SLS009 in early 2026.

Overall, BlackRock’s disclosure suggests growing institutional confidence in Sellas’s long-term potential despite the inherent risks of biotech investing. 

For investors, future valuation will likely hinge on the outcome of the REGAL trial, which could prove transformative if final data confirm the early survival benefit.

Featured image via Shutterstock

SummaryNeurocrine Biosciences is rated BUY, driven by strong INGREZZA sales, Prenepsi growth, and a promising late-stage neuropsychiatry pipeline.NBIX's Q2 2025 revenue reached $682 million, with INGREZZA contributing 91% and Prenepsi expanding its rare-disease market presence.Robust cash reserves of $1.8 billion and disciplined expense management position NBIX to self-fund pipeline innovation and future product launches.Key risks include revenue concentration in INGREZZA, pricing pressures, and clinical pipeline uncertainty, but NBIX's competitive edge and growth prospects remain compelling. J Studios/DigitalVision via Getty Images

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock has had a stellar six-month performance with double-digit gains, recovering from 52-week lows recorded in April 2025. However, the past month has been slowish, with marginal losses of below one percent. That said, the

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

SummaryPayPal Holdings Inc. is undervalued, with a fair value estimate of $143/share versus its current price near $67, offering 114% upside.PYPL's strengths include robust free cash flow, omnichannel presence, trusted brand, and aggressive share buybacks, supporting long-term shareholder value.Key risks for PYPL are rising competition, increasing debt, regulatory fines, and operational vulnerabilities, though its innovation and scale remain advantages.Despite operational and regulatory risks, PYPL presents a compelling long-term investment opportunity in digital payments, trading at a significant discount to intrinsic value. hapabapa/iStock Editorial via Getty Images

Investment Thesis PayPal Holdings Inc. (NASDAQ:PYPL) presents a highly attractive investment opportunity. Its current P/E ratio of slightly under 15 underscores how the market continues to undervalue its long-term cash flow potential. Additionally, growth in net

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Disclaimer
The information provided by Moods Investment Research is for general informational and educational purposes only. It is not intended as, and does not constitute, financial, investment, tax, legal, or other advice. The content is not a solicitation or recommendation to buy, sell, or hold any securities or investment strategies.
All opinions expressed are based on current analysis and are subject to change without notice. While we strive for accuracy, Moods Investment Research makes no representation or warranty as to the completeness, accuracy, or reliability of any information provided. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Moods Investment Research and its founders, directors, or affiliates are not liable for any losses or damages arising from any reliance on the information provided.
The views expressed in this article are those of the author(s) and do not constitute investment advice. The author holds no position in PayPal. However, the author(s), including any editors or contributors (collectively referred to as “Moods and directors”), may or may not hold positions in other securities mentioned. Any such holdings are subject to change without notice.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Tesla (TSLA) reports third quarter earnings results on Wednesday, Oct. 22, with Wall Street expecting $26.27 billion in revenue and $0.53 in adjusted earnings per share (EPS). Investors anticipate fresh commentary from Tesla CEO Elon Musk, as well as insights into the electric vehicle (EV) maker's China sales and cheaper new models.

Traffic drives in view of a Boeing Co. production plant, where images of jets decorate the hangar doors on April 23, 2021, in Everett, Wash. Credit: AP Photo/Elaine Thompson, File

The Federal Aviation Administration said Friday it will allow Boeing to produce more 737 Max airplanes by increasing the monthly limit that it imposed after a door plug blew off an Alaska Airlines jet that the company built.

Boeing can now produce 42 Max jets per month, up from 38, after safety inspectors conducted extensive reviews of the aerospace company's manufacturing lines to ensure an increase in production can be done safely, the FAA said.

The agency had set a cap on production shortly after the terrifying January 2024 incident involving the Alaska Airlines 737 Max jet. In practice, though, the production rate fell well below the ceiling last year as the company contended with investigations and a machinists' strike that idled factories for almost eight weeks. But Boeing said over the summer that it had reached the monthly cap in the second quarter and would eventually seek the FAA's permission to start producing more of the planes.

A spokesperson for Boeing said Friday that the company followed a "disciplined process" to make sure it was ready to safely increase production, using safety guidelines and performance goals that it set with the FAA.

"We appreciate the work by our team, our suppliers and the FAA to ensure we are prepared to increase production with safety and quality at the forefront," Boeing said in a statement.

The FAA also said Friday this won't change the way it oversees Boeing production processes and its efforts to strengthen the company's safety culture, adding that FAA inspectors at Boeing plants have continued to work through the federal government shutdown that began Oct. 1.

Just last month, the FAA also restored Boeing's ability to perform final safety inspections on 737 Max jetliners and certify them for flight. Boeing hadn't been allowed to do that for more than six years, after two crashes of the then-new model killed 346 people. The FAA took full control over 737 Max approvals in 2019, after the second of the two crashes that were later blamed on a new software system Boeing developed for the aircraft.

Earlier this year, Boeing CEO Kelly Ortberg faced questions from a Senate committee about the production rate of the 737 Max, with lawmakers seeking reassurance from Ortberg that the company was prioritizing quality and safety over meeting production targets for profit.

"Just to be very clear, we won't ramp up production if the performance isn't indicating a stable production system," Ortberg said at the April hearing. "We will continue to work on getting to a stable system."

The incident involving the Alaska Airlines flight that prompted the production cap on Max jets was among a series of alleged safety violations by Boeing between September 2023 and February 2024 that led to the FAA seeking $3.1 million in fines from the company.

© 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation:
FAA allows Boeing to increase 737 Max production nearly two years after door plug flew off plane (2025, October 18)
retrieved 18 October 2025
from https://techxplore.com/news/2025-10-faa-boeing-max-production-years.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of FDUS, BXSL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

SummaryPizza Pizza Royalty Corp. benefits from its low-cost, low-capital, high-margin business model as its financials remain well-positioned.Its prudent management of the royalty pool ensures increasing royalty income per store, margin expansion, and robust cash flow to ensure sustained expansion and dividend payouts.Its valuation stays cheap with decent dividend yields, justifying some upside potential.Technicals have weakened recently, but the selloff has opened new entry points amid rebounding buying volume.ArtistGNDphotography/E+ via Getty Images

Three months after my initial analysis of Pizza Pizza Royalty Corp. (OTCPK:PZRIF) (TSX:PZA:CA), we saw more developments that continued to support my buy rating. Its strategic business model and sound fundamentals ensure its

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PZA:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Nvidia (NASDAQ: NVDA) CEO Jensen Huang has sold a substantial amount of company stock, continuing his renewed selling spree amid the equity’s rally.

Filings indicate that over the past three weeks, Huang offloaded more than $250 million worth of NVDA shares under a pre-arranged Rule 10b5-1 trading plan adopted on March 20, 2025.

Between September 24 and October 15, 2025, Huang executed five sales of 225,000 Nvidia shares each. For instance, on October 15, he sold shares at an average price of $183.73, generating $41.3 million, and on October 10, another batch at $190.61 per share for $42.9 million.

NVDA CEO insider stock sales. Source: Barchart
This fits a broader six-month trend in which Huang sold around 5.5 million shares. Experts note such sales are typical for executives receiving RSUs that vest over time.

Despite significant insider selling, analysts see little impact on Nvidia’s outlook. Its 2024 share buyback, which cut the share count by 0.52%, and $11 billion in net cash helped offset dilution, while institutional investors added $70 billion in holdings in Q1 2025. Notably, significant insider sales tend to trigger caution among investors leading to bearish sentiments. 

Analysts bullish on Nvidia stock price 
Recent insider selling has not shaken market optimism, as Nvidia continues to lead the rapidly growing AI chip market. Wall Street remains bullish, with analysts seeing the semiconductor as central to the AI revolution with potential for accelerated stock rally. 

Despite the wave of insider selling, estimates from 38 analysts tracked by TipRanks set the average 12-month price target for Nvidia at $224.69, implying a 22.63% upside from the last closing price of $183.22. 

NVDA stock 12-month stock price chart. Source: TipRanks
The most optimistic forecast values the stock at $320.00, while the lowest estimate stands at $155.

Featured image via Shutterstock

RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Demonstrates Durable 5-Year Survival Benefit Vs Chemotherapy for Patients With Advanced Endometrial Carcinoma.

Media Release

COPENHAGEN, Denmark; October 18, 2025

Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expressionA Phase 3 trial in endometrial cancer is underwayU.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancer
Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective response rate (ORR), including two complete responses (CR), in heavily pretreated patients with advanced endometrial cancer (EC) who had progressed following platinum-based chemotherapy and an immune checkpoint inhibitor. Additionally, at a median study follow-up of one year, 63.6% of responders (including CRs) in the 100 mg/m² cohort maintained their responses and remain on treatment. The responses were observed regardless of FRα expression levels. The updated results were presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.

Continued evaluation of single-agent Rina-S 100 mg/m2 in patients with advanced EC is ongoing in the Phase 2 RAINFOL-01 trial (NCT05579366) and the Phase 3 RAINFOL-03 trial (NCT07166094).

“Women with advanced endometrial cancer are often facing a difficult path, while doctors are confronted with not having enough treatment options,” said Noelle Cloven, M.D., Texas Oncology Fort Worth, Sarah Cannon Research Institute, and study investigator. “That’s why these data signals with Rina-S in the updated Phase 1/2 RAINFOL-01 data are encouraging – they point to the possibility of providing more choices for patients in the future.”

The B2 cohort of the Phase 1/2 RAINFOL-01 study (NCT05579366) is a dose expansion cohort evaluating the efficacy and safety of Rina-S in patients with advanced or recurrent endometrial cancer. In the study, 64 patients with heavily pretreated advanced or recurrent endometrial cancer whose disease had progressed on or after an anti-PD-(L)1 and platinum-based chemotherapy were enrolled and treated with Rina-S. Patients were administered either 100 mg/m2 (n=22) (selected dose for Phase 3 clinical trial) or 120 mg/m2 (n=42) of Rina-S. In the 100 mg/m2 cohort, the confirmed ORR was 50.0%, including two CRs. Anti-tumor activity was also observed in patients treated with Rina-S 120 mg/m2 Q3W, which resulted in 44.1% confirmed ORR and one CR. Study participants were previously treated with a median of three lines of therapy (range 1-8). Earlier results from this cohort were previously presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

Common treatment emergent adverse events (TEAEs; all grades) consisted primarily of cytopenias and low-grade gastrointestinal (GI) events. To date, there have been no signals of ocular toxicities, neuropathy, or interstitial lung disease (ILD) observed in Rina-S clinical trials consistent with prior reports. Serious TEAEs (Grade 3 or higher), occurred in 36.4% and 52.4% of patients treated with Rina-S 100 mg/m2 and 120 mg/m2, respectively. Hematologic adverse events did not require significant dose reduction and were associated with low rates of treatment discontinuation.

“With this updated data, we are seeing additional momentum behind the possibilities of Rina-S,” said Tahi Ahmadi, M.D., Executive Vice President and Chief Medical Officer, Head of Experimental Medicines at Genmab. “As a wholly owned, novel antibody-drug conjugate, Rina-S reflects Genmab’s vision to accelerate our innovative, late-stage pipeline that has the potential to redefine possibilities for patients with certain gynecologic cancers.”

Rina-S is advancing through late-stage development supported by a growing portfolio of clinical trials, including the ongoing Phase 1/2 RAINFOL-01 trial (NCT05579366), the Phase 3 RAINFOL-03 trial (NCT07166094) in patients with endometrial cancer now underway and the Phase 3 RAINFOL-02 trial (NCT06619236) in patients with platinum resistant ovarian cancer (PROC). The U.S. Food and Drug Administration (FDA) recently granted Breakthrough Therapy Designation (BTD) to Rina-S for the treatment of adult patients with recurrent or progressive EC who have disease progression on or following prior treatment with a platinum-containing regimen and a PD-(L)1 therapy.

About the RAINFOLTM -01 Trial
RAINFOL™-01 (NCT05579366) is an open-label, multicenter Phase 1/2 study, designed to evaluate the safety and efficacy of rinatabart sesutecan (Rina-S) Q3W at various doses in solid tumors that are known to express FRα. The study consists of multiple parts including Part A dose escalation; Part B tumor-specific monotherapy dose-expansion cohorts; Part C platinum-resistant ovarian cancer (PROC) cohort; Part D combination therapy cohorts; Part F a monotherapy endometrial cancer (EC) cohort.

About Endometrial Cancer
Endometrial cancer (EC) starts in the lining of the uterus, known as the endometriumi and ranks as the second most prevalent gynecologic cancer globally, with increasing incidence and mortality ratesii,iii. Patients with advanced or recurrent EC have a relatively poor prognosis and treatment options are limited for those patients who have progressed following treatment with chemotherapy and immune checkpoint inhibitor. FRα is overexpressed on multiple tumors, including EC, making it a promising therapeutic target. Anti-tumor activity with Rina-S was observed across a broad range of FRα expression, and there are currently no approved FRα-directed therapies approved for the treatment of endometrial cancer.

About Rinatabart Sesutecan (Rina-S; GEN1184)
Rinatabart sesutecan (Rina-S; GEN1184) is an investigational ADC. It is composed of a novel human monoclonal antibody directed at folate receptor α (FRα), a novel hydrophilic protease-cleavable linker, and exatecan, a topoisomerase I inhibitor payload. The clinical trial program for Rina-S continues to expand including ovarian, endometrial and other cancers of unmet need.

The safety and efficacy of rinatabart sesutecan has not been established. Please visit www.clinicaltrials.gov for more information.

About Genmab 
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. 

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Contact:        
David Freundel, Senior Director, Global Communications & Corporate Affairs
T: +1 609 613 0504; E: [email protected]

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: [email protected]

This Media Release contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect®, KYSO® and RAINFOL™; Rina-S is a trademark of ProfoundBio, US, Co. and Genmab (Suzhou) Co., Ltd.

i Mayo Clinic. Endometrial Cancer. https://www.mayoclinic.org/diseases-conditions/endometrial-cancer/symptoms-causes/syc-20352461.
ii Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: Cancer today (version 1.1). International Agency
for Research on Cancer. 05/28/2024 (https://gco.iarc.who.int/today).
iii Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2021;31(1):12-39. (In eng). DOI: 10.1136/ijgc-2020-002230.

Media Release no. i18
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

18102025_i18_RINASESMOEC

Analyst’s Disclosure:I/we have a beneficial long position in the shares of NSRGY, NSRGF either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws.

If you invested in Jefferies or Point Bonita, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

Why are Jefferies and Point Bonita being Investigated?

Jefferies is an investment banking and capital markets firm. Its trade finance arm is named Point Bonita Capital. Jefferies and Point Bonita were two of the closest banking and financing partners of First Brands Group, LLC, an auto parts supplier which collapsed into bankruptcy in September 2025.

On October 8, 2025, Jefferies announced that it and Point Bonita had approximately $715 million in exposure to First Brands’ receivables, which represents roughly 25% of Point Bonita’s trade finance portfolio. On this news, the price of Jefferies stock fell $4.66 per share, or about 8%, from $59.10 per share on October 7, 2025, to $54.44 per share on October 8, 2025. Investors are reportedly currently seeking redemptions from Point Bonita as well.

BFA is currently investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors in connection with this significant exposure to First Brands.

Click here for more information: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

What Can You Do?

If you invested in Jefferies or Point Bonita you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.

HANetf co-CEO Hector McNeil spoke to Proactive about rising investor demand for gold and defense ETFs amid global geopolitical tensions.

He outlined the performance of HANetf's gold-related products and defense-themed funds, and discussed how ETFs are helping investors hedge against volatility and currency risk.

Here, we taka a closer look at what was said.

Proactive: Hector, very good to speak with you again. It's been a very active time geopolitically over the past couple of months. And we've seen that reflected both in defence stocks but also in the gold price with the gold price topping $4,000 an ounce.

Tell us about that, because you give exposure to gold both through your Gold Mining ETF as well as Physical Gold ETC.

Hector McNeil: Yes, funny enough, I don't know if I ever told you, Stephen, but my previous company — the first ETF I worked at was ETF Securities and we were well known for inventing the first gold ETF in the world. And I actually said it on a call with a company today that, when we issued that gold ETF back in 2003, gold was $318 an ounce.

So, it just shows you how far the world’s gone since then. I think, actually, ETFs have a lot to answer for, for the rise in demand, because ultimately, they make it very straightforward for people to put gold in their portfolios. Rather than you put it under the bed or in the safe, dig a hole in the ground or whatever, you can safely go and buy your ounce of gold and buy it through a gold ETF.

That's where people have got 5 to 8% of their portfolio in gold now — and that’s what I pretty well recommend people to do anyway. It was very hard to do that before. So, yeah, we have both the physical gold side with the Royal Mint.

We've just got a smidgen under £2 billion in RMAU, which is our showcase gold ETC with the Royal Mint. That’s just under £1.65 billion, and then we created currency-hedged versions earlier this year. They're nearly £300 million now. We've done Swiss franc hedged, euro hedged, and GBP hedged.

So, obviously with Trump devaluing the dollar so aggressively, those are great trades to put on. And then, as you've quite mentioned, we do have a Gold Miners ETF, which had been pretty dormant for a long time in terms of inflows. Then it’s tripled in size, it's up to £65 million now, nearly £70 million.

And it's tripling in the last three or four weeks. I think people see gold miners as a geared play to the gold price. So if you want a leveraged play to the gold price, the gold miners are the place to go. What’s really nice about the Gold Mining ETF (ESGO) as well, it has an ESG screen.

We do screen out companies that we feel are not meeting that high standard. And obviously, in gold companies, there can be a lot of toxicity in mining. That’s where Physical Gold ETC (RMAU) differentiates, because it uses recycled gold, which is 98% less carbon intensive than mined gold because of the toxicity and the logistics involved in moving it around.

Then you've got the other side of the story with ESGO, which is the gold miners. So we’re very happy with both of those products. We feel we've got a very curated offering in that space — whether it’s physical gold, whether it's miners, or whether it’s currency hedged. There are five products there that are very interesting for people to use.

Proactive: So while the gold price has clearly benefited from geopolitical tensions and given its safe haven status, we've also seen the defence stocks doing very well. And due to those tensions, you now have three defence ETFs. So you've got your Global Defence, European Defence, and also the newest addition to the family, your Indo-Pacific Defence ETC. How has that done?

Hector McNeil: Yeah. The global defence one is NATO-focused, which screens just for NATO companies. That's unique. NATO's a defensive alliance, and we think it's really important to have that sort of screen — because you don't want to be putting money in companies that are looking to invade everybody.

Having the NATO screen gives an official capital markets way to invest and support those companies as well. We all know the threats we have with the likes of Russia, North Korea, and China. So from that perspective, it’s a great product.

Then we have ARMY, which is the European product — that's a couple of hundred million. So we're getting almost £3.5 billion now in defence products.

Return-wise, the Gold Mining ETF (ESGO) has had a 130% return this year, which is just insane. It shows the geopolitical impact on gold.

Then, as you mentioned, our newest product is Indo-Pacific x China — that includes countries like Japan, Australia, Korea, India, etc. These are, to some extent, the extension of NATO for that region. It obviously buttresses against the geopolitical dominance of China and areas like North Korea.

Certainly, the performance has been insane for some of those countries. I think some Indian stocks are seeing 500% returns over that time. You probably saw over the weekend that Pakistan had a border skirmish with the Taliban, where over 100 soldiers were killed between the two countries.

In that Indo-Pacific region, we are one geopolitical event away from that being probably a couple of billion as well. I somewhat think if I’d been around when the India-Pakistan war had been in place, then it would have seen a big insight from there.

But QUAD is a very exciting ETF and rounds out our defence offering. Funnily enough, we've just added to our tech megatrend product, ITEK, which has eight megatrends, including cloud, social media, and transport. We just included AI, quantum computing, and defence tech in that basket as well.

So you get those eight megatrends all in one go. We think by adding in defence, it's updating that index to represent what's going on. We've got four products in that space today.

We think with gold and defence, you're pretty well hedged against dollar devaluation and geopolitical events, which seem to be the order of the day at the moment.

Proactive: It looks like that may continue to be the case for quite some time. Hector, as always, thank you very much for your time.

With over four years of experience in covering and tracking the financial markets, Sneha Agrawal is a dedicated Crypto Journalist and Editor with passion for researching and writing the crypto pieces. She is currently leading the Block of Fame, here at CoinGape. She likes to keep track of political, legal and financial happenings all around the world - without which she deems her day incomplete. Apart from her Journalistic endeavours, she is a solo traveler, museum goer, and a keen reader of books.

XRP Whale and Mid-Tier Wallets Hit All-Time High as Accumulation StrengthensAccording to leading on-chain analytics platform Santiment, wallets holding 10,000 or more XRP have reached an all-time high of over 317,500 addresses, signaling intensified accumulation among whales and mid-tier investors. 

Source: SantimentThis milestone underscores growing confidence in XRP’s long-term outlook, even as short-term market volatility persists.

The data show that both whales and mid-tier investors are aggressively accumulating XRP despite recent price swings, a clear sign of growing confidence in its long-term potential. 

Therefore, this steady accumulation often precedes major market moves, suggesting informed investors are positioning early for a potential breakout.

XRP’s price has rebounded by approximately 5.3% in the past 12 hours after finding a local bottom, highlighting renewed buying activity at lower levels. This modest but significant uptick aligns with the increasing wallet counts, reinforcing the narrative that accumulation is providing a solid demand floor.

Historically, spikes in wallet growth among large and mid-sized holders have preceded notable price recoveries in XRP and other major cryptocurrencies. 

When deep-pocketed investors continue to accumulate, it often reflects growing conviction that the asset is undervalued relative to its long-term fundamentals.

Beyond short-term price movements, the expanding base of large holders could signal a structural shift in market sentiment, with investors increasingly viewing XRP as a strategic asset tied to real-world utility. 

The token’s connection to cross-border payment solutions and its alignment with ISO 20022 standards continue to make it a strong candidate for institutional adoption.

XRP Eyes Potential Rebound Amid Descending Channel FormationAccording to market analyst Degen Profit, XRP is currently trading at $2.37, showing signs of cautious consolidation within a descending channel. 

This technical pattern, often associated with corrective phases, has historically preceded substantial rallies for the cryptocurrency, sparking optimism among traders and investors.

Source: Degen ProfitThe key to XRP’s next move lies in its ability to maintain support within the critical $2.00–$2.20 zone. This range has historically acted as a strong foundation, providing a potential springboard for upward momentum. 

Should buyers successfully defend this level, XRP could be positioned for a rebound toward the next resistance at $2.72. A successful breach of this level could open the door to further gains, with $3.32 emerging as a significant target for mid-term bullish momentum.

Therefore, market sentiment has turned cautiously bullish as traders track XRP’s support levels, volume trends, and broader crypto movements. A rebound could gain momentum if Bitcoin and Ethereum recover, potentially sparking a wider altcoin rally.

ConclusionThe record surge in wallets holding more than 10,000 XRP signals a pivotal shift in market dynamics. Whales and mid-tier holders are steadily accumulating, reflecting strong confidence in XRP’s long-term potential and the attractiveness of current prices. 

As buying pressure grows and network participation expands, XRP’s foundation strengthens, setting the stage for a sustained, conviction-driven bullish phase led by the asset’s most influential stakeholders.

Notably, XRP sits at a pivotal $2.00–$2.20 support zone. Holding this level could spark a rebound toward $2.72, and potentially $3.32, as buyers step in within the descending channel, setting the stage for a bullish turnaround despite short-term volatility.

Whales added 1.45 billion DOGE, worth about $268 million, and a daily close above $0.217 could lift DOGE toward $0.30.Two whale cohorts pushed Cardano holdings to 5.6 billion ADA, adding roughly $150 million — a close above $0.68 could open the path to $0.76.Whales and mega whales accumulated over 7 million BROCCOLI, worth nearly $170,000, and a breakout above $0.027 could extend gains to $0.043.After two sharp market drops this month, altcoins are again drawing attention from large investors. Despite broader caution, crypto whales appear to be positioning early for a rebound, buying key altcoins ahead of the expected October rate cuts.

With another Fed cut likely on the cards, three altcoins are quietly seeing strong inflows. Whales are buying these altcoins during dips, signaling early positioning and growing conviction.

Dogecoin (DOGE)First on the list is Dogecoin (DOGE). It is one of the few altcoins seeing clear signs of whale accumulation even after a steep correction.

Sponsored

Sponsored

The meme token has dropped more than 34% in the past 30 days, but crypto whales appear to be buying the dip. This could be in anticipation of the October rate cuts.

According to on-chain data, the whale cohort holding 100 million to 1 billion DOGE began increasing their supply again after October 16.

Their combined holdings rose from 28.16 billion DOGE to 29.61 billion DOGE. This means they’ve added roughly 1.45 billion DOGE — worth about $268 million at the current DOGE price.

Dogecoin Whales Accumulate: SantimentWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

This renewed accumulation comes just as the daily chart shows a standard bullish divergence between price and RSI, a momentum indicator.

Between June 22 and October 10, DOGE’s price made a lower low, while the Relative Strength Index (RSI) made a higher low — often a sign of a potential trend reversal.

If Dogecoin can close a daily candle above $0.188 and $0.217, it could confirm recovery momentum. From there, the next resistance levels lie at $0.242, $0.269, and even $0.306 in the short to mid-term.

Dogecoin Price Analysis: TradingViewHowever, if the price slips below $0.170, the bullish setup could weaken.

Sponsored

Sponsored

With the FedWatch now showing a 100% chance of an October rate cut, whales appear to be betting on easing monetary policy.

Cardano (ADA)Next on the list is Cardano (ADA) — another altcoin seeing sizable whale accumulation even as its price struggles. ADA has fallen nearly 32% over the past 30 days, but large holders appear to be using the weakness to position early, just as crypto whales did with Dogecoin.

Two key whale cohorts have been accumulating aggressively. The larger group, holding over 1 billion ADA, started buying on October 12, raising their holdings from 1.5 billion to 1.59 billion ADA, and has held steady since.

A second cohort — wallets with 100 million to 1 billion ADA — began adding a day later, on October 13, increasing their supply from 3.91 billion to 4.07 billion ADA.

They’ve added in stages across October 14, 16, and 17, showing steady conviction during ADA’s decline.

Two Cardano Whale Groups Buying: SantimentSponsored

Sponsored

At the current Cardano (ADA) price of $0.62, these whales have added roughly $150 million worth of ADA in under a week. This growing accumulation despite falling prices shows that larger holders are anticipating a possible trend reversal.

And, they might be taking advantage of discounted price levels.

On the daily chart, ADA shows a strong bullish divergence between price and RSI. Between February 9 and October 10, ADA’s price made a lower low, while the Relative Strength Index (RSI) made a higher low — a signal that bearish momentum is weakening.

Cardano Price Analysis: TradingViewCurrently, ADA trades around $0.62, but a daily candle close above $0.68 could confirm a breakout. If that happens, this altcoin could target $0.76, $0.89, and even $1.01, led by the October rate cut push.

However, if the price slips below $0.61, the structure could weaken, opening the path toward $0.50.

CZ’s Dog (BROCCOLI)Rounding off the list is BROCCOLI (CZ’s Dog). It is an offbeat yet increasingly popular altcoin that’s been quietly gaining traction ahead of the expected October rate cuts.

Sponsored

Sponsored

Unlike Dogecoin and Cardano, BROCCOLI isn’t among the top tokens by market cap. Yet, its whale accumulation pattern shows it’s starting to attract serious interest.

Over the past 24 hours, BROCCOLI has slipped just 4.4%, while its seven-day loss remains limited to 2.4%. This shows strong relative resilience despite the broader market dip. And this stability seems to be catching the attention of large investors.

Data shows that whale holdings of BROCCOLI rose 8.9% in the past day. Additionally, mega whales — the top 100 addresses — added 0.65% to their holdings.

Combined, these cohorts accumulated over 7 million BROCCOLI tokens in 24 hours, worth close to $170,000 at the current BROCCOLI price.

Even as “smart money” wallets reduced exposure by over 40%, the whale and mega whale accumulation reflects growing conviction in the token’s near-term outlook.

BROCCOLI Whales: NansenThe Money Flow Index (MFI) — a momentum indicator that measures buying and selling pressure using both price and trading volume — is showing a clear bullish divergence.

Between August 7 and October 14, BROCCOLI’s price made a lower low, but the MFI formed a higher low. This means retail inflows are rising even as prices decline, suggesting growing accumulation rather than panic selling.

BROCCOLI Price Analysis: TradingViewTo confirm strength, BROCCOLI needs to close above $0.027, which could open a rally toward $0.035 and $0.043. On the other hand, a dip below $0.018 would weaken the structure and signal further downside.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

The cryptocurrency Fear & Greed Index has plummeted into the extreme fear territory following the crash in Bitcoin and other assets.

Bitcoin Fear & Greed Index Is Now Pointing At “Extreme Fear”
The “Fear & Greed Index” is an indicator created by Alternative that uses the data of several factors to determine the net sentiment present among traders in the Bitcoin and wider cryptocurrency markets. The factors in question include volatility, trading volume, market cap dominance, social media sentiment, and Google Trends.

The index makes use of a scale running from 0-100 for representing the investor mentality. All values above 53 imply the traders are greedy, while those below 47 suggest a fearful market. Values lying between the two cutoffs correspond to a net neutral sentiment.

Besides these three main sentiments, there are also two “extreme” zones called the extreme fear (below 25) and extreme greed (above 75). Currently, the market is in the former of the two.

Looks like the metric has a value of 22 | Source: Alternative
As displayed above, the Fear & Greed Index has a value of 22 at the moment, which is just inside the extreme fear zone. This is a deterioration compared to the last few days, when the indicator held normal fear values.

How the metric has changed over the past year | Source: Alternative
The reason behind the slide into the extreme fear territory naturally lies in the bearish action that Bitcoin and other cryptocurrencies have faced recently. In particular, the market has suffered a sharp move down during the past day.

Last week also ended with a rapid drawdown in BTC and company, and then too sentiment took a large hit, with the index registering a low of 24. This previous turnaround in sentiment was also much more drastic than the latest one, as it took the metric from greed values all the way down into the extreme fear zone in a flash.

Historically, the extreme sentiments have held much importance for Bitcoin and other digital assets, as major tops and bottoms have often occurred in these regions. The relationship has been an inverse one, however, meaning that extreme fear can result in a bottom, while extreme greed can lead to a top.

The plunge into extreme fear earlier also paved the way to a bottom, although it proved to be only a temporary one. With the Fear & Greed Index back in the zone, it will be interesting to see how the Bitcoin price will develop in the coming days.

BTC Price
At the time of writing, Bitcoin is trading around $105,600, down 13% over the last week.

The trend in the price of the coin over the last five days | Source: BTCUSDT on TradingView
Featured image from Dall-E, Alternative.me, chart from TradingView.com

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

The Ethereum price has risen 2.74% in the past 24 hours to trade at $3,892.28. A market analyst believes Ethereum is mirroring a previous rally that led to massive gains earlier this year. At the same time, institutional interest continues to grow as whales and asset managers expand their exposure to ETH. Bitmine has notably added a significant amount of ETH to its treasury, strengthening accumulation signals. 

Ethereum Price Action: Chart Mirrors Mid-Year Breakout Structure
The Ethereum price is replicating a similar structure to the mid-year rally that began in July. Back then, ETH broke out of its accumulation zone on July 9 and rallied by 83%, peaking near $4,960 in late August. 

The current chart shows another accumulation phase forming between $3,600 and $4,200, reflecting the same consolidation pattern that preceded the earlier breakout. Notably, both setups feature a fakeout above the accumulation zone, which was followed by a strong rebound leading to a sustained rally. 

Analyst Ash Crypto emphasized that this recurring setup could once again trigger a sharp upward move, potentially propelling ETH price above $5,000 before targeting $7,000 by Q4. The pattern reflects renewed buying activity among large holders, reinforcing the possibility of another parabolic advance. 

In the context of a long-term Ethereum price prediction, maintaining strength above $4,200 would confirm the breakout structure and sustain the bullish outlook. However, a dip below $3,600 could briefly stall the rally before recovery resumes.

ETH/USDC 1-Day Chart (Source: X)
Bitmine’s ETH Treasury Expansion Boosts Confidence
Large investors have intensified accumulation, reinforcing bullish conviction for Ethereum price growth in the coming months. Lookonchain reported that Bitmine recently expanded its ETH treasury through multiple wallet transactions linked to FalconX and BitGo. 

This follows a prior large-scale purchase in which Bitmine added over $417 million worth of ETH to its holdings, marking one of its biggest accumulation phases this year. The trend mirrors a broader institutional shift after BlackRock reportedly sold Bitcoin and accumulated 12,098 ETH from Coinbase Prime. 

These moves highlight rising confidence in Ethereum’s ecosystem and its long-term potential as a preferred institutional asset. Notably, such large acquisitions often precede strong price expansions as exchange supply continues to tighten. 

Meanwhile, the network’s consistent activity further supports this accumulation phase. Together, these factors strengthen the technical and fundamental case for an end-of-year rally.

To sum up, Ethereum appears well-positioned for another strong advance if the breakout pattern holds. Institutional and whale accumulation are reinforcing the bullish framework shaping across charts. The ETH price could approach $7,000 if current structures remain intact through Q4. Altogether, Ethereum’s renewed buying interest signals that bullish control is firmly reestablishing itself.

Short-term and long-term NUPL metrics show multi-month lows, signaling exhaustion and possible market bottoming.Hidden bullish divergence on RSI suggests XRP’s larger uptrend may soon resume after weeks of correction.Death crossovers completed, with $2.44 and $2.59 acting as key breakout levels to confirm a new recovery trend.XRP price has dropped nearly 23% over the past 30 days, extending one of its steepest declines this quarter. However, the token has shown its first signs of recovery — rising 6% in the past 24 hours — as several technical and on-chain metrics suggest the worst may be over.

Together, these signals point to fading selling pressure and the early signs of a potential rebound.

Sponsored

Investor Losses Hint at a Market BottomRecent on-chain data shows that investors are reaching exhaustion, a sign often seen when a market is close to bottoming out.

The Net Unrealized Profit/Loss (NUPL) measures whether investors are sitting on profits or losses. When it turns deeply negative, it means most holders are in loss, usually a sign of capitulation.

For XRP, the short-term holder NUPL has now dropped to a one-year low of –0.20 as of October 17, with the token trading near $2.30.

The last time it reached such local lows was in April and June, both followed by sharp rebounds. For example, on April 8, when NUPL hit –0.13, XRP gained 20% in four days. On June 22, with NUPL at –0.15, it rallied 74% in a month.

Short-term Holders Are At a Loss: GlassnodeWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Sponsored

The long-term holder NUPL, which tracks older investors, has also fallen to a six-month low of 0.53. A similar low earlier this month led to a short-term XRP price bounce from $2.38 to $2.62, a 10% rise.

Profits For Long-Term Holders Diminishing: GlassnodeBoth readings dropping together suggest widespread fatigue among holders and a potential setup for recovery.

Momentum Indicators Support the Reversal ViewThe XRP price momentum is now validating the on-chain losses reflected by NUPL. The Relative Strength Index (RSI) — a technical tool that measures how strong or weak price movements are — is showing what’s known as a hidden bullish divergence.

Sponsored

Between April 7 and October 10, XRP’s price formed a higher low, while RSI made a lower low. This usually happens when the market is still in an uptrend but is temporarily cooling off. The signal suggests that, despite recent weakness, the underlying strength of XRP, since April, remains intact.

XRP Divergence Hinting At An Uptrend: TradingViewThis alignment between NUPL exhaustion and RSI divergence reinforces the idea that XRP’s correction could be ending, setting the stage for an early recovery.

Sponsored

Key Levels to Confirm an XRP Price RecoveryThe technical XRP price structure also supports this view. Three death crossovers — where short-term moving averages cross below longer ones — have already completed. The 20-day EMA has fallen under the 100-day and 200-day, and the 50-day has dropped below the 100-day.

These signals often appear near the end of a bearish phase, suggesting the correction may have run its course.

The Exponential Moving Average (EMA) is a line that smooths price data to show the overall direction more clearly.

The XRP price trades near $2.35 at press time. A daily close above $2.44 would mark the first sign of strength, while a confirmed move above $2.59 — near the 200-day EMA — could clear the way toward $2.82 and $3.10.

XRP Price Analysis: TradingViewIf the price slips below $2.28, however, the recovery setup would weaken, and the XRP price could retest support at $2.08 or even $1.77, likely its broader cycle bottom.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

For months, investors believed buying shares in Bitcoin treasury companies like MicroStrategy and Metaplanet was the smarter, safer way to gain exposure to the world’s largest cryptocurrency. It felt like a shortcut to Bitcoin profits until the Bitcoin treasury bubble bursts.

According to a new report by 10x Research, retail investors have lost over $17 billion chasing these so-called “Bitcoin treasury” stocks. And the crash didn’t come from a fall in Bitcoin’s price, but from something far more painful.

Sky-High Premiums Come Crashing DownDuring 2024 and early 2025, excitement around Bitcoin’s institutional adoption reached its peak. Investors began paying 3 to 4x their net asset value (NAV) just to own shares in Bitcoin-holding companies, treating them like leveraged bets on crypto’s future.

But as global markets cooled and Trump’s trade tensions with China added uncertainty, these inflated valuations couldn’t hold. 

Multiples collapsed to around 1.0–1.4× NAV, erasing billions in shareholder value, even while Bitcoin’s price stayed near record highs. Overall, 10x Research estimates that around $20 billion was overpaid, showing the cost of chasing hype over real assets.

Metaplanet & MicroStrategy Struggle TooMetaplanet, once called “Asia’s MicroStrategy,” stopped buying Bitcoin in early October after its share price fell nearly 47% in just three weeks, pushing its enterprise value below the worth of its BTC holdings. The company alone lost $4.9 billion from its peak.

MicroStrategy was not spared either; its premium fell sharply from 4× to 1.4× NAV, showing how even established players felt the squeeze.

How Investors Lost Big10x Research calls this the end of the “financial magic.” These treasury firms, once celebrated for their bold Bitcoin strategies, now face pressure to prove real value through lending, custody, or arbitrage.

The crash was simple math: companies bought Bitcoin with stock or debt at inflated prices. When valuations cooled, investors who bought at the peak lost about 67% compared to holding Bitcoin directly.

As a result, many are shifting to spot Bitcoin ETFs or direct holdings, where transparency is better and premiums don’t erode returns.

10X Research further warns the premium collapse could erase $25–30 billion in value by year-end, hitting speculative Bitcoin capital further. To survive, firms must now earn 15–20% returns through real yield strategies—or risk collapse.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Bittensor price is grabbing headlines today after surging more than 14% in the last 24 hours and notching a 23% gain over the past week. This rally has lifted TAO’s market cap to an impressive $4 billion. The spark? Grayscale announced new institutional interest with its Bittensor Trust filing. This powerful combination of fresh capital, technical breakout, and sustained spot accumulation is driving sentiment and price.

TAO Price AnalysisOn the 4-hour chart, TAO price has decisively reclaimed the $403.65 Fibonacci 23.6% retracement level, flipping it back into support. Notably, the token is now holding above its 7-day SMA at $394.36. Recent price action shows a sharp rebound from $345.41, confirming that bulls defended the pivot point at $371.4. The latest pulse in the MACD histogram (+7.71) reveals that bullish momentum is still accelerating. Meanwhile, the RSI sits at 55, suggesting there’s still room for additional upside.

What does this mean for traders? The breakout above $403 validates the short-term bullish trend. As long as TAO stays above the $371.4 pivot, dips are likely to be bought. Immediate upside targets include $433.9, with a potential move to the next resistance at $478.27. Should bulls clear this level, the path opens toward $564, which aligns with the 127.2% Fibonacci extension.

FAQsWhy did Bittensor’s (TAO) price rally today?

TAO spiked due to renewed institutional demand, notably from Grayscale’s Trust news, bullish technical confirmation. And robust spot accumulation that offset derivative profit-taking.

What are the major support and resistance levels for TAO now?

Key support is at $371.4, while resistance levels remain at $433.9, $478.27, and $564 if the breakout continues.

Is TAO overbought, or does it have further upside potential?

With the RSI at 55, TAO has not yet reached overbought territory, suggesting further room for price appreciation if technical and market momentum hold.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.